Blood Reviews
Volume 20, Issue 5 , Pages 245-266 , September 2006

Pathogenesis of neutropenia in large granular lymphocyte leukemia and Felty syndrome

  • Eric J. Burks

      Affiliations

    • Harvard School of Medicine, Brigham and Women’s Hospital, Department of Pathology, 75 Francis Street, Boston, MA 02115, United States
    • Corresponding Author InformationCorresponding author. Tel.: +617 732 7510; fax: +617 277 9015.
    • ,
  • Thomas P. Loughran Jr.

      Affiliations

    • Penn State University, College of Medicine, Milton S. Hershey Medical Center, Department of Medicine, Division of Hematology/Oncology, Penn State Cancer Institute, 500 University Drive, M.C.H072 Hershey, PA 17033, United States
    • Tel.: +717 531 1078; fax: +717 531 0002.

References 

  1. Loughran TP. Clonal diseases of large granular lymphocytes. Blood. 1993;82:1–14
  2. Loughran TP, Kadin ME, Starkebaum G, Abkowitz JL, Clark EA, Disteche C, et al. Leukemia of large granular lymphocytes: association with clonal chromosomal abnormalities and autoimmune neutropenia, thrombocytopenia, and hemolytic anemia. Ann Intern Med. 1985;102:169–175
  3. Burks EJ, Loughran TP. Large Granular Lymphocyte Leukemia. In:  Young NS,  Gerson SL,  High KA editor. Clinical Hematology. first ed.. Philadelphia: Elsevier; 2006;p. 216–230
  4. Lamy T, Loughran TP. Large Granular Lymphocyte Leukemia. Cancer Control. 1998;5:25–33
  5. Semenzato G, Pandolfi F, Chisesi T, De Rossi G, Pizzolo G, Zambello R, et al. The lymphoproliferative disease of granular lymphocytes. A heterogeneous disorder ranging from indolent to aggressive conditions. Cancer. 1987;60:2971–2978
  6. Semenzato G, Zambello R, Starkebaum G, Oshimi K, Loughran TP. The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood. 1997;89:256–260
  7. Evans HL, Burks E, Viswanatha D, Larson RS. Utility of immunohistochemistry in bone marrow evaluation of T-lineage large granular lymphocyte leukemia. Hum Pathol. 2000;31:1266–1273
  8. Morice WG, Kurtin PJ, Tefferi A, Hanson CA. Distinct bone marrow findings in T-cell granular lymphocytic leukemia revealed by paraffin section immunoperoxidase stains for CD8, TIA-1, and granzyme B. Blood. 2002;99:268–274
  9. Felty AR. Chronic arthritis in the adult associated with splenomegaly and leukopenia: A report of five cases of an unusual clinical syndrome. Bulletin of the Johns Hopkins Hospital. 1924;35:16–20
  10. Spivak JL. Felty’s syndrome: an analytical review. Johns Hopkins Med J. 1977;141:156–162
  11. French LE, Lessin SR, Addya K, Denardo B, Margolis DJ, Leonard DG, et al. Identification of clonal T cells in the blood of patients with systemic sclerosis: positive correlation with response to photopheresis. Arch Dermatol. 2001;137:1309–1313
  12. Bigouret V, Hoffmann T, Arlettaz L, Villard J, Colonna M, Ticheli A, et al. Monoclonal T-cell expansions in asymptomatic individuals and in patients with large granular leukemia consist of cytotoxic effector T cells expressing the activating CD94:NKG2C/E and NKD2D killer cell receptors. Blood. 2003;101:3198–3204
  13. Posnett DN, Sinha R, Kabak S, Russo C. Clonal populations of T cells in normal elderly humans: the T cell equivalent to “benign monoclonal gammapathy”. J Exp Med. 1994;179:609–618
  14. Dippel E, Klemke D, Hummel M, Stein H, Goerdt S. T-cell clonality of undetermined significance. Blood. 2001;98:247–248
  15. Lamy T, Loughran TP. Clinical features of large granular lymphocyte leukemia. Semin Hematol. 2003;40:185–195
  16. Rosenstein ED, Kramer N. Felty’s and pseudo-Felty’s syndromes. Semin Arthritis Rheum. 1991;21:129–142
  17. Gordon DA, Stein JL, Broder I. The extra-articular features of rheumatoid arthritis. A systematic analysis of 127 cases. Am J Med. 1973;54:445–452
  18. Snowden N, Bhavnani M, Swinson DR, Kendra JR, Dennett C, Carrington P, et al. Large granular T lymphocytes, neutropenia and polyarthropathy: an underdiagnosed syndrome?. Q J Med. 1991;78:65–76
  19. Campion G, Maddison PJ, Goulding N, James I, Ahern MJ, Watt I, et al. The Felty syndrome: a case-matched study of clinical manifestations and outcome, serologic features, and immunogenetic associations. Medicine (Baltimore). 1990;69:69–80
  20. Osuji N, Matutes E, Dearden C, Catovsky D. Pregnancy improves neutropenia in T-cell large granular lymphocyte leukaemia. Br J Haematol. 2005;128:645–648
  21. Loughran TP, Starkebaum G. Large granular lymphocyte leukemia. Report of 38 cases and review of the literature. Medicine (Baltimore). 1987;66:397–405
  22. Gordon GV. Rheumatoid vasculitis. Int J Dermatol. 1981;20:546–547
  23. Pun YL, Barraclough DR, Muirden KD. Leg ulcers in rheumatoid arthritis. Med J Aust. 1990;153:585–587
  24. Thorne C, Urowitz MB, Wanless I, Roberts E, Blendis LM. Liver disease in Felty’s syndrome. Am J Med. 1982;73:35–40
  25. Agnarsson BA, Loughran TP, Starkebaum G, Kadin ME. The pathology of large granular lymphocyte leukemia. Hum Pathol. 1989;20:643–651
  26. Snowden N, Kay RA. Immunology of systemic rheumatoid disease. Br Med Bull. 1995;51:437–448
  27. Harris ED. Excitement–and confusion–about HLA and rheumatoid arthritis. Ann Intern Med. 1995;123:232–233
  28. Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum. 1987;30:1205–1213
  29. Wordsworth P, Pile KD, Buckely JD, Lanchbury JS, Ollier B, Lathrop M, et al. HLA heterozygosity contributes to susceptibility to rheumatoid arthritis. Am J Hum Genet. 1992;51:585–591
  30. Bowman SJ, Sivakumaran M, Snowden N, Bhavnani M, Hall MA, Panayi GS, et al. The large granular lymphocyte syndrome with rheumatoid arthritis. Immunogenetic evidence for a broader definition of Felty’s syndrome. Arthritis Rheum. 1994;37:1326–1330
  31. Nepom GT, Nepom BS. Prediction of susceptibility to rheumatoid arthritis by human leukocyte antigen genotyping. Rheum Dis Clin North Am. 1992;18:785–792
  32. Starkebaum G, Loughran TP, Gaur LK, Davis P, Nepom BS. Immunogenetic similarities between patients with Felty’s syndrome and those with clonal expansions of large granular lymphocytes in rheumatoid arthritis. Arthritis Rheum. 1997;40:624–626
  33. Breedveld FC, Fibbe WE, Hermans J, van der Meer JW, Cats A. Factors influencing the incidence of infections in Felty’s syndrome. Arch Intern Med. 1987;147:915–920
  34. Palmblad JE, von dem Borne AE. Idiopathic, immune, infectious, and idiosyncratic neutropenias. Semin Hematol. 2002;39:113–120
  35. Boxer L, Dale DC. Neutropenia: causes and consequences. Semin Hematol. 2002;39:75–81
  36. Welte K, Boxer LA. Severe chronic neutropenia: pathophysiology and therapy. Semin Hematol. 1997;34:267–278
  37. Hanrahn E, Miller S. Effect of splenectomy in Felty’s syndrome. JAMA. 1932;99:1247–1252
  38. Bucknall RC, Davis P, Bacon PA, Jones JV. Neutropenia in rheumatoid arthritis: studies on possible contributing factors. Ann Rheum Dis. 1982;41:242–247
  39. Laszlo J, Jones R, Silberman HR, Banks PM. Splenectomy for Felty’s syndrome. Clinicopathological study of 27 patients. Arch Intern Med. 1978;138:597–602
  40. Green RA, Fromke VL. Splenectomy in Felty’s syndrome. Ann Intern Med. 1966;64:1265–1270
  41. Barnes CG, Turnbull AL, Vernon-Roberts B. Felty’s syndrome. A clinical and pathological survey of 21 patients and their response to treatment. Ann Rheum Dis. 1971;30:359–374
  42. Moore RA, Brunner CM, Sandusky WR, Leavell BS. Felty’s syndrome: long-term follow-up after splenectomy. Ann Intern Med. 1971;75:381–385
  43. Rashba EJ, Rowe JM, Packman CH. Treatment of the neutropenia of Felty syndrome. Blood Rev. 1996;10:177–184
  44. Schnitzer B. Reactive Lymphoid Hyperplasias. In:  Jaffe ES editors. Surgical Pathology of the Lymph Nodes and Related Organs. second ed.. Philadelphia: W.B. Saunders Company; 1995;p. 98–132
  45. De Gruchy GC, Langley GR. Felty’s syndrome. Australas Ann Med. 1961;10:292–303
  46. O’Neill JA, Scott HW, Billings FT, Foster JH. The role of splenectomy in Felty’s syndrome. Ann Surg. 1968;167:81–84
  47. Osuji N, Matutes E, Catovsky D, Lampert I, Wotherspoon A. Histopathology of the spleen in T-cell large granular lymphocyte leukemia and T-cell prolymphocytic leukemia: a comparative review. Am J Surg Pathol. 2005;29:935–941
  48. Sandusky WR, Rudolf LE, Leavell BS. Splenectomy for control of neutropenia in Felty’s syndrome. Ann Surg. 1968;167:744–751
  49. Foucar K, Duncan MH, Smith KJ. Practical approach to the investigation of neutropenia. Clin Lab Med. 1993;13:879–894
  50. Collier RL, Brush BE. Hematologic disorder in Felty’s syndrome. Prolonged benefits of splenectomy. Am J Surg. 1966;112:869–873
  51. Foucar K. Constitutional and Reactive Myeloid Disorders. In:  Foucar K editors. Bone Marrow Pathology. second ed.. Chicago: ASCP Press; 2001;p. 147–172
  52. Dancey JT, Brubaker LH. Neutrophil marrow profiles in patients with rheumatoid arthritis and neutropenia. Br J Haematol. 1979;43:607–617
  53. Dogan A, Morice WG. Bone marrow histopathology in peripheral T-cell lymphomas. Br J Haematol. 2004;127:140–154
  54. Bagby GC, Lawrence HJ, Neerhout RC. T-lymphocyte–mediated granulopoietic failure. In vitro identification of prednisone-responsive patients. N Engl J Med. 1983;309:1073–1078
  55. Aprile JA, Russo M, Pepe MS, Loughran TP. Activation signals leading to proliferation of normal and leukemic CD3+ large granular lymphocytes. Blood. 1991;78:1282–1285
  56. Perzova R, Loughran TP. Constitutive expression of Fas ligand in large granular lymphocyte leukaemia. Br J Haematol. 1997;97:123–126
  57. Epling-Burnette PK, Loughran TP. Survival signals in leukemic large granular lymphocytes. Semin Hematol. 2003;40:213–220
  58. Maas K, Westfall M, Pietenpol J, Olsen NJ, Aune T. Reduced p53 in peripheral blood mononuclear cells from patients with rheumatoid arthritis is associated with loss of radiation-induced apoptosis. Arthritis Rheum. 2005;52:1047–1057
  59. Schneider E, Moreau G, Arnould A, Vasseur F, Khodabaccus N, Dy M, et al. Increased fetal and extramedullary hematopoiesis in Fas-deficient C57BL/6-lpr/lpr mice. Blood. 1999;94:2613–2621
  60. Barcena A, Park SW, Banapour B, Muench MO, Mechetner E. Expression of Fas/CD95 and Bcl-2 by primitive hematopoietic progenitors freshly isolated from human fetal liver. Blood. 1996;88:2013–2025
  61. Kim H, Whartenby KA, Georgantas RW, Wingard J, Civin CI. Human CD34+ hematopoietic stem/progenitor cells express high levels of FLIP and are resistant to Fas-mediated apoptosis. Stem Cells. 2002;20:174–182
  62. Nagafuji K, Shibuya T, Harada M, Mizuno S, Takenaka K, Miyamoto T, et al. Functional expression of Fas antigen (CD95) on hematopoietic progenitor cells. Blood. 1995;86:883–889
  63. Nagafuji K, Takenaka K, Shibuya T, Harada M, Niho Y. Fas antigen (CD95) and hematopoietic progenitor cells. Leuk Lymphoma. 1996;24:43–56
  64. Takenaka K, Nagafuji K, Harada M, Mizuno S, Miyamoto T, Makino S, et al. In vitro expansion of hematopoietic progenitor cells induces functional expression of Fas antigen (CD95). Blood. 1996;88:2871–2877
  65. Maciejewski J, Selleri C, Anderson S, Young NS. Fas antigen expression on CD34+ human marrow cells is induced by interferon gamma and tumor necrosis factor alpha and potentiates cytokine-mediated hematopoietic suppression in vitro. Blood. 1995;85:3183–3190
  66. Sato T, Selleri C, Anderson S, Young NS, Maciejewski JP. Expression and modulation of cellular receptors for interferon-gamma, tumour necrosis factor, and Fas on human bone marrow CD34+ cells. Br J Haematol. 1997;97:356–365
  67. Maciejewski JP, Selleri C, Sato T, Anderson S, Young NS. Increased expression of Fas antigen on bone marrow CD34+ cells of patients with aplastic anaemia. Br J Haematol. 1995;91:245–252
  68. Hooks JJ, Haynes BF, Detrick-Hooks B, Diehl LF, Gerrard TL, Fauci AS. Gamma (immune) interferon production by leukocytes from a patient with a TG cell proliferative disease. Blood. 1982;59:198–201
  69. Bank I, Cohen L, Kneller A, De Rosbo NK, Book M, Ben-Nun A. Aberrant T-cell receptor signalling of interferon-gamma- and tumour necrosis factor-alpha-producing cytotoxic CD8+ Vdelta1/Vbeta16 T cells in a patient with chronic neutropenia. Scand J Immunol. 2003;58:89–98
  70. Papadaki HA, Eliopoulos AG, Kosteas T, Gemetzi C, Damianaki A, Koutala H, et al. Impaired granulocytopoiesis in patients with chronic idiopathic neutropenia is associated with increased apoptosis of bone marrow myeloid progenitor cells. Blood. 2003;101:2591–2600
  71. Papadaki HA, Eliopoulos GD. The role of apoptosis in the pathophysiology of chronic neutropenias associated with bone marrow failure. Cell Cycle. 2003;2:447–451
  72. Koumaki V, Papadaki HA, Stefanaki K, Damianaki A, Gemetzi C, Katonis P, et al. Increased cell apoptosis in bone marrow trephine biopsies and immunomagnetically isolated myeloid progenitor cells in patients with chronic idiopathic neutropenia. Ann Hematol. 2003;82:641–645
  73. Starkebaum G, Singer JW, Arend WP. Humoral and cellular immune mechanisms of neutropenia in patients with Felty’s syndrome. Clin Exp Immunol. 1980;39:307–314
  74. Liles WC, Kiener PA, Ledbetter JA, Aruffo A, Klebanoff SJ. Differential expression of Fas (CD95) and Fas ligand on normal human phagocytes: implications for the regulation of apoptosis in neutrophils. J Exp Med. 1996;184:429–440
  75. Ribeiro-Gomes FL, Moniz-de-Souza MC, Borges VM, Nunes MP, Mantuano-Barradas M, D’Avila H, et al. Turnover of neutrophils mediated by Fas ligand drives Leishmania major infection. J Infect Dis. 2005;192:1127–1134
  76. Liu JH, Wei S, Lamy T, Epling-Burnette PK, Starkebaum G, Djeu JY, et al. Chronic neutropenia mediated by fas ligand. Blood. 2000;95:3219–3222
  77. Tanaka M, Suda T, Haze K, Nakamura N, Sato K, Kimura F, et al. Fas ligand in human serum. Nat Med. 1996;2:317–322
  78. Cheung MM, Chan JK, Wong KF. Natural killer cell neoplasms: a distinctive group of highly aggressive lymphomas/leukemias. Semin Hematol. 2003;40:221–232
  79. Reichard KK, Burks EJ, Foucar MK, Wilson CS, Viswanatha DS, Hozier JC, et al. CD4(+) CD56(+) lineage-negative malignancies are rare tumors of plasmacytoid dendritic cells. Am J Surg Pathol. 2005;29:1274–1283
  80. Ogasawara J, Watanabe-Fukunaga R, Adachi M, Matsuzawa A, Kasugai T, Kitamura Y, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806–809
  81. Starkebaum G, Arend WP, Nardella FA, Gavin SE. Characterization of immune complexes and immunoglobulin G antibodies reactive with neutrophils in the sera of patients with Felty’s syndrome. J Lab Clin Med. 1980;96:238–251
  82. Goldschmeding R, Breedveld FC, Engelfriet CP, von dem Borne AE. Lack of evidence for the presence of neutrophil autoantibodies in the serum of patients with Felty’s syndrome. Br J Haematol. 1988;68:37–40
  83. van der Veen JP, Goldschmeding R, Miedema F, Smit JW, Melief CJ, von dem Borne AE. K-cell lymphocytosis/neutropenia syndrome: the neutropenia is not caused by autoimmunity. Br J Haematol. 1986;64:777–787
  84. Ditzel HJ, Masaki Y, Nielsen H, Farnaes L, Burton DR. Cloning and expression of a novel human antibody-antigen pair associated with Felty’s syndrome. Proc Natl Acad Sci USA. 2000;97:9234–9239
  85. Ohkouchi K, Mizutani H, Tanaka M, Takahashi M, Nakashima K, Shimizu M. Anti-elongation factor-1alpha autoantibody in adult atopic dermatitis patients. Int Immunol. 1999;11:1635–1640
  86. Burks EJ, Starkebaum G, Loughran Jr TP. Section III. Large granular lymphocyte leukemia and neutropenia. In: Berliner N, Horwitz M, Loughran Jr TP. Congenital and acquired neutropenia. Hematology (Am Soc Hematol Educ Program); 2004:pp. 63–79.
  87. Starkebaum G, Stevens DL, Henry C, Gavin SE. Stimulation of human neutrophil chemiluminescence by soluble immune complexes and antibodies to neutrophils. J Lab Clin Med. 1981;98:280–291
  88. Hashimoto Y, Ziff M, Hurd ER. Increased endothelial cell adherence, aggregation, and superoxide generation by neutrophils incubated in systemic lupus erythematosus and Felty’s syndrome sera. Arthritis Rheum. 1982;25:1409–1418
  89. Breedveld FC, Lafeber GJ, de Vries E, van Krieken JH, Cats A. Immune complexes and the pathogenesis of neutropenia in Felty’s syndrome. Ann Rheum Dis. 1986;45:696–702
  90. Gamberale R, Giordano M, Trevani AS, Andonegui G, Geffner JR. Modulation of human neutrophil apoptosis by immune complexes. J Immunol. 1998;161:3666–3674
  91. Burks EJ, Loughran TP. Perspectives in the treatment of LGL leukemia. Leuk Res. 2005;29:123–125
  92. Genestier L, Paillot R, Fournel S, Ferraro C, Miossec P, Revillard JP. Immunosuppressive properties of methotrexate: apoptosis and clonal deletion of activated peripheral T cells. J Clin Invest. 1998;102:322–328
  93. Genestier L, Paillot R, Quemeneur L, Izeradjene K, Revillard JP. Mechanisms of action of methotrexate. Immunopharmacology. 2000;47:247–257
  94. Strauss G, Osen W, Debatin KM. Induction of apoptosis and modulation of activation and effector function in T cells by immunosuppressive drugs. Clin Exp Immunol. 2002;128:255–266
  95. Kothapalli R, Bailey RD, Kusmartseva I, Mane S, Epling-Burnette PK, Loughran TP. Constitutive expression of cytotoxic proteases and down-regulation of protease inhibitors in LGL leukemia. Int J Oncol. 2003;22:33–39
  96. Spits H, Yssel H, Leeuwenberg J, De Vries JE. Antigen-specific cytotoxic T cell and antigen-specific proliferating T cell clones can be induced to cytolytic activity by monoclonal antibodies against T3. Eur J Immunol. 1985;15:88–91
  97. Bowman SJ, Hall MA, Panayi GS, Lanchbury JS. T cell receptor alpha-chain and beta-chain junctional region homology in clonal CD3+, CD8+ T lymphocyte expansions in Felty’s syndrome. Arthritis Rheum. 1997;40:615–623
  98. O’Keefe CL, Plasilova M, Wlodarski M, Risitano AM, Rodriguez AR, Howe E, et al. Molecular analysis of TCR clonotypes in LGL: a clonal model for polyclonal responses. J Immunol. 2004;172:1960–1969
  99. Loughran TP, Kidd PG, Starkebaum G. Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood. 1994;84:2164–2170
  100. Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty’s syndrome. Br J Rheumatol. 1998;37:908–911
  101. Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with Felty’s syndrome. Correlation of response with neutrophil-reactive IgG. Arthritis Rheum. 1989;32:194–201
  102. Cronstein BN. Low-dose methotrexate: a mainstay in the treatment of rheumatoid arthritis. Pharmacol Rev. 2005;57:163–172
  103. Hasko G, Cronstein BN. Adenosine: an endogenous regulator of innate immunity. Trends Immunol. 2004;25:33–39
  104. Herman S, Zurgil N, Deutsch M. Low dose methotrexate induces apoptosis with reactive oxygen species involvement in T lymphocytic cell lines to a greater extent than in monocytic lines. Inflamm Res. 2005;54:273–280
  105. Phillips DC, Woollard KJ, Griffiths HR. The anti-inflammatory actions of methotrexate are critically dependent upon the production of reactive oxygen species. Br J Pharmacol. 2003;138:501–511
  106. Nesher G, Osborn TG, Moore TL. In vitro effects of methotrexate on polyamine levels in lymphocytes from rheumatoid arthritis patients. Clin Exp Rheumatol. 1996;14:395–399
  107. Thomas T, Thomas TJ. Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci. 2001;58:244–258
  108. Ha HC, Sirisoma NS, Kuppusamy P, Zweier JL, Woster PM, Casero RA. The natural polyamine spermine functions directly as a free radical scavenger. Proc Natl Acad Sci USA. 1998;95:11140–11145
  109. Huang CC, Hsu PC, Hung YC, Liao YF, Liu CC, Hour CT, et al. Ornithine decarboxylase prevents methotrexate-induced apoptosis by reducing intracellular reactive oxygen species production. Apoptosis. 2005;10:895–907
  110. Wakai A, Wang JH, Winter DC, Street JT, O’Sullivan RG, Redmond HP. Adenosine inhibits neutrophil vascular endothelial growth factor release and transendothelial migration via A2B receptor activation. Shock. 2001;15:297–301
  111. Flamand N, Boudreault S, Picard S, Austin M, Surette ME, Plante H, et al. Adenosine, a potent natural suppressor of arachidonic acid release and leukotriene biosynthesis in human neutrophils. Am J Respir Crit Care Med. 2000;161:S88–S94
  112. Cronstein BN. Adenosine, an endogenous anti-inflammatory agent. J Appl Physiol. 1994;76:5–13
  113. Nesher G, Mates M, Zevin S. Effect of caffeine consumption on efficacy of methotrexate in rheumatoid arthritis. Arthritis Rheum. 2003;48:571–572
  114. Ackeret C, Lluss HJ, Hitzig WH. Hereditary sever combined immunodeficiency and adenosine deaminase deficiency. Pediatr Res. 1976;10:67–70
  115. Friesen C, Herr I, Krammer PH, Debatin KM. Involvement of the CD95 (APO-1/FAS) receptor/ligand system in drug-induced apoptosis in leukemia cells. Nat Med. 1996;2:574–577
  116. Lamy T, Liu JH, Landowski TH, Dalton WS, Loughran TP. Dysregulation of CD95/CD95 ligand-apoptotic pathway in CD3 (+) large granular lymphocyte leukemia. Blood. 1998;92:4771–4777
  117. Sood R, Stewart CC, Aplan PD, Murai H, Ward P, Barcos M, et al. Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood. 1998;91:3372–3378
  118. Coutinho J, Lima M, dos Anjos Teixeira M, Cabeda JM, Leite F, Justica B. Pure red cell aplasia associated to clonal CD8+ T-cell large granular lymphocytosis: dependence on cyclosporin A therapy. Acta Haematol. 1998;100:207–210
  119. Gabor EP, Mishalani S, Lee S. Rapid response to cyclosporine therapy and sustained remission in large granular lymphocyte leukemia. Blood. 1996;87:1199–1200
  120. Coiffier B. Cyclosporine in Felty’s syndrome. N Engl J Med. 1986;314:184
  121. Canvin JM, Dalal BI, Baragar F, Johnston JB. Cyclosporine for the treatment of granulocytopenia in Felty’s syndrome. Am J Hematol. 1991;36:219–220
  122. Tugwell P, Pincus T, Yocum D, Stein M, Gluck O, Kraag G, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. The Methotrexate-Cyclosporine Combination Study Group. N Engl J Med. 1995;333:137–141
  123. Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclosporin A and FK506. Clin Immunol Immunopathol. 1996;80:S40–S45
  124. Bram RJ, Hung DT, Martin PK, Schreiber SL, Crabtree GR. Identification of the immunophilins capable of mediating inhibition of signal transduction by cyclosporin A and FK506: roles of calcineurin binding and cellular location. Mol Cell Biol. 1993;13:4760–4769
  125. Dhodapkar MV, Li CY, Lust JA, Tefferi A, Phyliky RL. Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance. Blood. 1994;84:1620–1627
  126. Anderson D, Bishop JB, Garner RC, Ostrosky-Wegman P, Selby PB. Cyclophosphamide: review of its mutagenicity for an assessment of potential germ cell risks. Mutat Res. 1995;330:115–181
  127. Job-Deslandre C, Menkes CJ. [Treatment of Felty’s syndrome accompanied by agranulocytosis using high-dose corticoids. 3 cases]. Presse Med. 1987;16:569–570
  128. Wyllie AH. Glucocorticoid-induced thymocyte apoptosis is associated with endogenous endonuclease activation. Nature. 1980;284:555–556
  129. Lanza L, Scudeletti M, Puppo F, Bosco O, Peirano L, Filaci G, et al. Prednisone increases apoptosis in in vitro activated human peripheral blood T lymphocytes. Clin Exp Immunol. 1996;103:482–490
  130. Northrop JP, Crabtree GR, Mattila PS. Negative regulation of interleukin 2 transcription by the glucocorticoid receptor. J Exp Med. 1992;175:1235–1245
  131. Bishop CR, Athens JW, Boggs DR, Warner HR, Cartwright GE, Wintrobe MM. Leukokinetic studies. 13. A non-steady-state kinetic evaluation of the mechanism of cortisone-induced granulocytosis. J Clin Invest. 1968;47:249–260
  132. Mulder AB, de Wolf JT, Smit JW, van Oostveen JW, Vellenga E. Correction of neutropenia by GM-CSF in patients with a large granular lymphocyte proliferation. Ann Hematol. 1992;65:91–95
  133. Kaneko T, Ogawa Y, Hirata Y, Hoshino S, Takahashi M, Oshimi K, et al. Agranulocytosis associated with granular lymphocyte leukaemia: improvement of peripheral blood granulocyte count with human recombinant granulocyte colony-stimulating factor (G-CSF). Br J Haematol. 1990;74:121–122
  134. Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty’s syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum. 1999;29:82–99
  135. Spiekermann K, Roesler J, Emmendoerffer A, Elsner J, Welte K. Functional features of neutrophils induced by G-CSF and GM-CSF treatment: differential effects and clinical implications. Leukemia. 1997;11:466–478
  136. Yong KL, Linch DC. Differential effects of granulocyte- and granulocyte-macrophage colony-stimulating factors (G- and GM-CSF) on neutrophil adhesion in vitro and in vivo. Eur J Haematol. 1992;49:251–259
  137. Loughran TP, Starkebaum G, Clark E, Wallace P, Kadin ME. Evaluation of splenectomy in large granular lymphocyte leukaemia. Br J Haematol. 1987;67:135–140
  138. Khan MA, Kushner I. Improvement of rheumatoid arthritis following splenectomy for Felty syndrome. Jama. 1977;237:1116–1118
  139. Blumfelder TM, Logue GL, Shimm DS. Felty’s syndrome: effects of splenectomy upon granulocyte count and granulocyte-associated IgG. Ann Intern Med. 1981;94:623–628
  140. McKenna RW, Parkin J, Kersey JH, Gajl-Peczalska KJ, Peterson L, Brunning RD. Chronic lymphoproliferative disorder with unusual clinical, morphologic, ultrastructural and membrane surface marker characteristics. Am J Med. 1977;62:588–596
  141. Siebert JD, Mulvaney DA, Potter KL, Fishkin PA, Geoffroy FJ. Relative frequencies and sites of presentation of lymphoid neoplasms in a community hospital according to the revised European-American classification. Am J Clin Pathol. 1999;111:379–386
  142. Foucar K. Chronic Lymphoproliferative Disorders. In: K F, ed. Bone Marrow Pathology (second ed.) Chicago: ASCP Press; 2001:pp. 366–405.
  143. Foucar K. B-cell chronic lymphocytic and prolymphocytic leukemia. In:  Knowles D editors. Neoplastic Hematopathology. second ed.. Philadelphia: Lippincott Williams & Wilkins; 2001;p. 1505–1529
  144. Johnston JB. Hairy-Cell Leukemia. In:  Lee GR,  Foerster J,  Lukens J,  Paraskevas F,  Greer JP,  Rodgers GM editor. Wintrobe’s Clinical Hematology. tenth ed.. Baltimore: Willimas & Wilkins; 1998;p. 2428–2446

PII: S0268-960X(06)00004-X

doi: 10.1016/j.blre.2006.01.003

Blood Reviews
Volume 20, Issue 5 , Pages 245-266 , September 2006

Article Tools

* Image Usage & Resolution